Quantitative Structure-Activity Relationship (QSAR) Studies for the Inhibition of MAOs.

Quantitative Structure-Activity Relationship (QSAR) Studies for the Inhibition of MAOs.

Publication date: Mar 24, 2020

Monoamine oxidases are the crucial drug target for the treatment of neurodegenerative disorders like depression, Parkinson’s disease, and Alzheimer’s disease. The enzymes catalyze the oxidative deamination of several monoamine containing neurotransmitters, i.e. serotonin (5-HT), melatonin, epinephrine, norepinephrine, phenylethylamine, benzylamine, dopamine, tyramine, etc. The oxidative reaction of monoamine oxidases results in the production of hydrogen peroxide that led to the neurodegeneration process. Therefore, the inhibition of monoamine oxidases has shown a profound effect against neurodegenerative diseases. At present, the design and development of newer lead molecules for the inhibition of monoamine oxidases is under the progress of intensive research in the field of medicinal chemistry. Recently, the advancement in QSAR methodologies has shown considerable interest in the development of monoamine oxidase inhibitors. The present review describes the development in QSAR methodologies, its role in the design of newer monoamine oxidase inhibitors. It will assist the medicinal chemist in the identification of selective and potent monoamine oxidase inhibitors from various chemical scaffolds.

Ramesh, M. and Arunachalam, M. Quantitative Structure-Activity Relationship (QSAR) Studies for the Inhibition of MAOs. 24459. 2020 Comb Chem High Throughput Screen.

Concepts Keywords
Alzheimer Neurodegenerative diseases
Benzylamine Psychoactive drugs
Catalyze Amphetamine
Depression Monoamine oxidase inhibitors
Dopamine Branches of biology
Drug Target TAAR1 agonists
Epinephrine Antidepressants
Hydrogen Peroxide Monoamine neurotransmitter
Medicinal Chemist Oxidative deamination
Medicinal Chemistry
Monoamine Oxidase Inhibitors
Neurodegenerative Diseases
Neurodegenerative Disorders


Type Source Name
disease MESH neurodegenerative disorders
disease MESH depression
drug DRUGBANK Serotonin
drug DRUGBANK Melatonin
drug DRUGBANK Epinephrine
drug DRUGBANK Norepinephrine
drug DRUGBANK Phenethylamine
drug DRUGBANK Benzylamine
drug DRUGBANK Dopamine
drug DRUGBANK Tyramine
drug DRUGBANK Hydrogen peroxide
pathway REACTOME Neurodegenerative Diseases
disease MESH development


Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *